• Home
  • NEW DAY MEDICINE
  • 12(50)2022
  • 3 -12 (50) 2022 — Ganiyeva N.A.,Rizamukhamedova M.Z. — PREDICTORS OF EARLY ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLERODERMA

3 -12 (50) 2022 — Ganiyeva N.A.,Rizamukhamedova M.Z. — PREDICTORS OF EARLY ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLERODERMA

PREDICTORS OF EARLY ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLERODERMA

Ganiyeva N.A. Tashkent Medical Academy

Rizamukhamedova M.Z. Tashkent Medical Academy

Resume

Target. To assess the incidence of traditional cardiovascular risk factors, clinical and subclinical manifestations of atherosclerosis in patients with systemic scleroderma (SS). Material and methods. We examined 70 patients with a reliable diagnosis of SS (66 women and 4 men), cf. age 46 ± 10.8 years. Control group – 50 “conditionally” healthy volunteers without systemic rheumatic diseases and Raynaud’s syndrome, matched by sex and age. Results. The prevalence of traditional cardiovascular risk factors and TFR% were comparable in patients with SS and in the control group. The frequency of menopause was higher in patients with SS (p=0.005). IHD was diagnosed more often in patients with SS (13% vs. 2%, p<0.05). The mean triglyceride level in SS patients was significantly higher than in the control group (p<0.001). There was a tendency to increase intima media thickness (TIM max.) and the frequency of thickening of the TIM complex in patients with SS compared with the control group. Conclusion. Among SS patients, there was a higher prevalence of clinical and subclinical manifestations of atherosclerosis compared with the control group, with no significant differences in the incidence of major cardiovascular risk factors.

Keywords: systemic scleroderma, atherosclerosis, cardiovascular risk factors.

First page

12

Last page

17

For citation: Ganiyeva N.A.,Rizamukhamedova M.Z. – PREDICTORS OF EARLY ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLERODERMA //New Day in Medicine 12(50)2022 12-17 https://clck.ru/3354HD

LIST OF REFERENCES:

  1. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. //Circulation, 2016, 109, III-27 – III-32.
  2. Matucci-Cerinic M., Valentini G., Sorano G.G. et al. Blood coagulation, fibrinolysis and markers of endothelial dysfunction in systemic sclerosis. //Sem. Arthr. Rheum., 2018, 32, 285–292.
  3. Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. //Circulation, 2017,112, 3337-3347.
  4. Sherer Y., Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. //Nat. Clin. Pract. Rheumatol., 2016, 2(2), 99-106.
  5. Ho M., Veale D., Eastmond C. et al. Macrovascular disease and systemic sclerosis. //Ann. Rheum. Dis., 2018, 59, 39-43.
  6. Matucci Cerinic M., Fiori G., Grenbaum E., Shoenfeld Y. Macrovascular disease in systemic sclerosis. In: Furst D, Clements P, eds. Systemic Sclerosis. Baltimore, Md: Lippincott Williams and Wilkins, 2019, 241.
  7. Taylor M.H., McFadden J.A., Bolster M.B. et al. Ulnar artery involvement in systemic sclerosis (scleroderma). //J. Rheumatol., 2017, 29(1), 102-106.
  8. Cheng K.S., Tiwari A., Boutin A. et al. Carotid and femoral arterial wall mechanics in scleroderma. //Rheumatology, 2015, 42, 1299–1305.
  9. Moyssakis I., Gialafos E., Vassiliou V. et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. //Rheumatology, 2015, 44, 251–254.
  10. Szucs G., Timar O., Szekanecz Z. et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis–relevance for prevention of vascular complications. //Rheumatology (Oxford), 2017, 46 (5), 759-762.
  11. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). //Circulation, 2017, 106, 3143.
  12. Assassi S., Swindell W.R., Wu M. et al. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis //Arthritis Rheum. – 2018. – Vol. 67, №11. – P. 3016-3026. DOI: 10.1002/art.39289.
  13. Ayers N.B., Sun C.M., Chen S.Y. Transforming growth factor-signaling in systemic sclerosis //J. Biomed. Res. – 2018. – Vol. 32, №1. – P. 3-12. DOI: 10.7555/ JBR.31.20170034.
  14. Bosello S., de Santis M., Lama G. et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial //Arthritis Res. Ther. – 2015. – Vol. 12, №2. – P. 54. DOI: 10.1186/ar2965.
  15. Ganiyeva N.A, Rizamukhamedova M.Z., Nabiyeva D.A., Aripova N.A. Clinic – Diagnostic Aspects of Modern Biomarkers of  Early Atherosclerosis and Fibrotic activity of Systemic Scleroderma //Asian Journal of Medical Principles and Clinical Practice. – 2021. – Vol. 4, №3. – P. 1-13.
  16. Costa S., Mondini M., Caneparo V. et al. Detection of anti IFI 16 antibodies by ELISA: Clinical and serological associations in systemic sclerosis //Rheumatol. – 2016. – Vol. 50, №4. – P. 674-681. DOI: 10.1093/rheumatology/ keq372.
  17. Farina G., Lafyatis D., Lemaire R. et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis //Arthritis Rheum. – 2010. – Vol. 62. – P. 580-588. DOI: 10.1002/art.27220.
  18. Fett N. Scleroderma: Nomenclature, etiology, pathogenesis, prognosis and treatments: Facts and controversies //Clin. Dermatol. – 2017. – Vol. 31, №4. – P. 432-437. DOI: 10.1016/j. clindermatol.2013.01.010.
  19. Gheita T.A., Hussein H. Cartilage Oligomeric Matrix Protein (COMP) in Systemic Sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap //Joint Bone Spine. – 2016. – Vol. 79. – P. 51-56. DOI:10.1016/j. jbspin.2011.02.022.
  20. Pizzorni C., Sulli A., Smith V., Ruaro B., Trombetta A.C., Cutolo M., Paolino S. Primary Raynaud’s phenomenon and nailfold videocapillaroscopy: Age-related changes in capillary morphology //Clin Rheumatol. – 2017. – Vol. 36. – P. 1637-1642.

file

download